Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 16/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20710506 | 0.89 | GBA1 (0.65) | GBA1MAPK1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL20710471 | 0.89 | GBA1 (0.65) | GBA1MAPK1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL20710424 | 0.80 | GBA1 (0.54) | GBA1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20710490 | 0.80 | GBA1 (0.54) | GBA1USP2ALDH1A1 | |
| SCHEMBL20710493 | 0.78 | GBA1 (0.52) | GBA1USP2ALDH1A1 | |
| SCHEMBL22403212 | 0.78 | GBA1 (0.52) | GBA1MAPK1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL22403117 | 0.77 | GBA1 (1.00) | GBA1 | |
| SCHEMBL20710511 | 0.75 | GBA1 (0.80) | GBA1 | |
| SCHEMBL20710535 | 0.75 | GBA1 (0.80) | GBA1 | |
| SCHEMBL20710440 | 0.74 | GBA1 (0.94) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| WO-2019027765-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THERE | NORTHWESTERN UNIVERSITY (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | GBA3, GBA1, GBA2 | GBA1 2/4885MAPK1 4091/4885SMN1; SMN2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.